Program
Dendritic Cell
Its studies are mostly in Diabetic Nephropathies · Glioblastoma · Prostatic Neoplasms, led by 2 companies.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Northwest Biotherapeutics | 20 open or running | phase 3since Aug 6, 2002 | Aug 6, 2002 | none ahead |
| PT. JES Kasih Nusantara Sejahterah | 11 open or running | phase 2since Feb 22, 2025 | Feb 22, 2025 | none ahead |
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Aug 6, 2002First study: phase 3 study in Prostatic NeoplasmsNew to Northwest BiotherapeuticsNorthwest Biotherapeutics · NCT00043212 · United States
- Sep 17, 2002Phase 3 study in GlioblastomaNorthwest Biotherapeutics · NCT00045968 · 348 enrolled · United States, Canada, Germany and more
- Feb 22, 2025PT. JES Kasih Nusantara Sejahterah's first study: phase 2 study in Diabetic NephropathiesNew to PT. JES Kasih Nusantara SejahterahPT. JES Kasih Nusantara Sejahterah · NCT06866158 · 80 enrolled · Indonesia
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 3 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT06866158Diabetic Nephropathies · Indonesia | 2 | Active, not recruiting | PT. JES Kasih Nusantara Sejahterah | Aug 5, 2024 | 80 |
| NCT00045968Glioblastoma · United States, Canada, Germany and more | 3 | UNKNOWN | Northwest Biotherapeutics | Nov 2022 | 348 |
| NCT00043212Prostatic Neoplasms · United States | 3 | Withdrawn | Northwest Biotherapeutics | 0 |
How it is read
Names in the registry
- “Dendritic cell immunotherapy”, 3 entries
Conditions, from the studies’ own filings
- Diabetic Nephropathies, 1 study
- Glioblastoma, 1 study
- Prostatic Neoplasms, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.